ImageneBio | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -2.91.

Cash Position

As of September 30, 2025, ImageneBio, Inc. had cash, cash equivalents, and marketable securities totaling $142.6 million, a significant increase from $12.1 million as of December 31, 2024. This increase was primarily due to the merger between Inmagene Biopharmaceutics and Ikena Oncology, Inc., along with a $75.0 million private placement.

Research and Development (R&D) Expenses

R&D expenses for the three months ended September 30, 2025, were $15.6 million, compared to $3.9 million for the same period in 2024. The $11.7 million increase was mainly due to higher clinical trial expenses and non-cash stock-based compensation expenses following the merger.

General and Administrative (G&A) Expenses

G&A expenses for the three months ended September 30, 2025, were $11.0 million, up from $1.7 million for the same period in 2024. The $9.3 million increase was primarily attributed to a $5.2 million rise in stock-based compensation and increased professional services and compensation costs.

Net Loss

The net loss for the three months ended September 30, 2025, was $24.8 million, compared to $3.2 million for the same period in 2024. The $21.6 million increase was due to additional operating costs related to the merger and associated transaction costs.

Outlook / Guidance

ImageneBio plans to submit a protocol amendment for the ongoing Phase 2b ADAPTIVE study to expand dosing regimens and optimize study design, aiming to demonstrate the differentiated potential of IMG-007. Topline data from the study is expected in 2027.